MedTrace Logo

Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis

NCT00332904 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2010-06-04

No results posted yet for this study

Summary

The study´s purpose is to investigate the effect of beta blockade or aldosterone antagonist therapy on oxygenation, peripheral and cardiac hemodynamics and humoral systems, in patients with liver cirrhosis.

Conditions

Interventions

DRUG

propranolol

tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment

DRUG

spironolactone

tablet 200 mg pr. day in 3 weeks, evt. dose adjustment

Sponsors & Collaborators

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Soeren Moeller, MD, DMSc · Hvidovre University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-07-31
Completion
2010-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332904 on ClinicalTrials.gov